Trial Profile
A Phase I Investigator-Initiated Study of Selinexor (KPT-330) Plus RICE in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Carboplatin; Dexamethasone; Etoposide; Ifosfamide; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Richter's syndrome
- Focus Adverse reactions
- Acronyms KPT-330+RICE
- 10 Apr 2022 Status changed from active, no longer recruiting to completed.
- 20 Sep 2021 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021.
- 23 Jun 2021 Planned End Date changed from 1 Apr 2021 to 1 Aug 2021.